Title : Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib.

Pub. Date : 2009 Sep 21

PMID : 19920925






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The development of novel agents designed to overcome IM resistance, while still primarily targeted on BCR-ABL, led to the creation of the high affinity aminopyrimidine inhibitor, nilotinib. 2-aminopyrimidine ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens